Abstract
Background: Clomiphene is normally used in women with ovulatory dysfunction. In men, it is used off label in some cases of infertility. Psychological adverse effects are reported in women but very few in men.
Case: A 34-year-old man treated with clomiphene for oligoteratospermia presented anxiety, decreased appetite, and mood change making him unable to function properly at work, five days after initiation of therapy. Symptoms required reduction followed by discontinuation of treatment four days later because of absence of improvement. Following cessation, the patient noted a gradual then a complete resolution approximately one week later. The patient did not have any psychiatric or other medical condition neither drug nor substance abuse that could explain this clinical presentation. The Naranjo's score was used to prove the clomiphene's imputability.
Conclusion: Health care providers should advise patients of the risk of psychological adverse effects when initiating treatment with clomiphene and should provide a close monitoring of mood change, especially during the initial weeks.
Keywords: Anxiety, clomiphene, drug-related side effects and adverse reactions, infertility, male, mood disorders.
Current Drug Safety
Title:Clomiphene for the Treatment of Male Infertility: A Case Report of Mood Change and a Literature Overview
Volume: 12 Issue: 3
Author(s): Marine Aussedat, Jennifer Jean-Louis, Orchidee Djahangirian and Marie-Sophie Brochet*
Affiliation:
- CHU Sainte-Justine, 3175 Chemin de la Cote-Sainte-Catherine, Montreal (Quebec) H3T 1C5,Canada
Keywords: Anxiety, clomiphene, drug-related side effects and adverse reactions, infertility, male, mood disorders.
Abstract: Background: Clomiphene is normally used in women with ovulatory dysfunction. In men, it is used off label in some cases of infertility. Psychological adverse effects are reported in women but very few in men.
Case: A 34-year-old man treated with clomiphene for oligoteratospermia presented anxiety, decreased appetite, and mood change making him unable to function properly at work, five days after initiation of therapy. Symptoms required reduction followed by discontinuation of treatment four days later because of absence of improvement. Following cessation, the patient noted a gradual then a complete resolution approximately one week later. The patient did not have any psychiatric or other medical condition neither drug nor substance abuse that could explain this clinical presentation. The Naranjo's score was used to prove the clomiphene's imputability.
Conclusion: Health care providers should advise patients of the risk of psychological adverse effects when initiating treatment with clomiphene and should provide a close monitoring of mood change, especially during the initial weeks.
Export Options
About this article
Cite this article as:
Aussedat Marine, Jean-Louis Jennifer, Djahangirian Orchidee and Brochet Marie-Sophie *, Clomiphene for the Treatment of Male Infertility: A Case Report of Mood Change and a Literature Overview, Current Drug Safety 2017; 12 (3) . https://dx.doi.org/10.2174/1574886312666170616092036
DOI https://dx.doi.org/10.2174/1574886312666170616092036 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dietary Patterns in Alzheimers Disease and Cognitive Aging
Current Alzheimer Research Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry The Role of Bile Acids in Pancreatic Cancer
Current Cancer Drug Targets The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Himalayan Plants as a Source of Anti-Cancer Agents: A Review
The Natural Products Journal MicroRNA: The Potential Regulator of Endometrial Carcinogenesis
MicroRNA Does Gut-breast Microbiota Axis Orchestrates Cancer Progression?
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy New Uses of Melatonin as a Drug; A Review
Current Medicinal Chemistry Mesenchymal Stem Cells, Immune Cells and Tumor Cells Crosstalk: A Sinister Triangle in the Tumor Microenvironment
Current Stem Cell Research & Therapy Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways
Current Cancer Drug Targets Association of Genetic Variants with Colorectal Cancer in the Extended MENA Region: A Systematic Review
Current Molecular Medicine Cardiovascular Physiology of Androgens and Androgen Testosterone Therapy in Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Protective Effects of Downregulating Estrogen Receptor Alpha Expression in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry